CWA
VRTX icon

Cura Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Cura Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$399K Buy
803
+43
+6% +$19.1K 0.17% 72
2026
Q1 		$339K Hold
760
– – 0.15% 76
2025
Q4 		$344K Buy
760
+26
+4% +$11.2K 0.13% 81
2025
Q3 		$287K Buy
734
+159
+28% +$66.5K 0.11% 87
2025
Q2 		$256K Buy
+575
New +$265K 0.1% 86

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cura Wealth Advisors's VRTX Position: Q2 2026 in Review

Cura Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 5.7% in Q2 2026, buying an estimated $19.1K and bringing the position to 803 shares worth $399K. The position accounts for 0.17% of the portfolio, ranked #72.

Cura Wealth Advisors first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Cura Wealth Advisors held 803 shares of Vertex Pharmaceuticals worth $399K as of Q2 2026.
  • Cura Wealth Advisors bought 43 Vertex Pharmaceuticals shares in Q2 2026, an estimated $19.1K.
  • Vertex Pharmaceuticals made up 0.17% of Cura Wealth Advisors's portfolio in Q2 2026, its #72 holding.
  • Cura Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Cura Wealth Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.